Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276853 | 0.89 | CRHR1 (0.37) | CRHR1ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL3269600 | 0.85 | CRHR1 (0.46) | CRHR1ALDH1A1HDAC1SMN1; SMN2CYP1A2 | |
| SCHEMBL2191084 | 0.84 | CRHR1 (0.45) | CRHR1ALDH1A1KDM4EHDAC1SMN1; SMN2 | |
| SCHEMBL2189061 | 0.84 | CRHR1 (0.42) | CRHR1ALDH1A1KDM4EHPGDHDAC1 | |
| SCHEMBL2192531 | 0.83 | CRHR1 (0.40) | CRHR1ALDH1A1KDM4EHPGDHDAC1 | |
| SCHEMBL2190727 | 0.83 | CRHR1 (0.43) | CRHR1P2RX7 | |
| SCHEMBL2190760 | 0.83 | CRHR1 (0.42) | CRHR1ALDH1A1KDM4EHPGDHDAC1 | |
| SCHEMBL2192423 | 0.83 | CRHR1 (0.39) | CRHR1HDAC1P2RX7 | |
| SCHEMBL2190779 | 0.82 | CRHR1 (0.43) | CRHR1ALDH1A1KDM4EHPGDHDAC1 | |
| SCHEMBL2192396 | 0.82 | CRHR1 (0.42) | CRHR1HDAC1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | CRHR1 1/4885ALDH1A1 3578/4885KDM4E 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.